Roivant Sciences (ROIV) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ROIV Roivant Sciences

Watchlist

11.920
+0.010+0.08%

Close Oct 18 16:00 ET

11.783
-0.137-1.15%

Post 20:01 ET

8.82BMarket Cap2.08P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Price Over Earnings Overview: Roivant Sciences
BenzingaOct 18 11:15 ET
Roivant Sciences (ROIV): High-Growth UK Stock With Innovative Drug Development Model
Yahoo FinanceOct 17 14:32 ET
12 Health Care Stocks Moving In Thursday's After-Market Session
BenzingaOct 3 16:31 ET
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
BenzingaOct 3 08:43 ET
Roivant Sciences(ROIV.US) Insider Sells US$10.94 Million in Common Stock
Moomoo NewsSep 26 21:28 ET
Roivant Sciences(ROIV.US) Director Sells US$5.87 Million in Common Stock
Moomoo NewsSep 26 20:39 ET

Comments

Meltyy

May 16 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

Movers and Shakers

Apr 2 07:16

Columns Today's Morning Movers and Top Ratings: DIS, DASH, CVS, GE and More

Morning Movers
Gapping up
$DoorDash (DASH.US)$ stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential.
$Roivant Sciences (ROIV.US)$ stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study.
Gapping down
$NIO Inc (NIO.US)$ fell ...

Meltyy

Jan 24 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...

Moomoo AI

Jan 5 04:55

The sale of Roivant Sciences shares by an insider, without any recent insider buying, and a high insider ownership can signal mixed sentiments towards the company's future prospects. It could perpetuate caution among potential investors.